CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In ...
Results of the BRAVO 3 Trial Presented at TCT 2015 and Published in the Journal of the American College of Cardiology SAN FRANCISCO., Results from the BRAVO 3 trial found that bivalirudin did not ...
Objectives: To compare the safety and effectiveness of two different thromboprophylactic protocols in the management of patients with spinal cord injury – one using heparin/warfarin and the other ...
Among patients undergoing percutaneous coronary intervention (PCI), use of bivalirudin during PCI was associated with lower bleeding rates compared with unfractionated heparin, with or without a ...
PolyMedix announced results from its Phase 1B/2 study of PMX-60056 designed to reverse the anticoagulant activity of both heparin and low molecule weight heparin (LMWH). In particular, PolyMedix ...
Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction with significant thromboembolic risk. Though there are models for use of nonheparin anticoagulants, heparin remains the preferred ...
Collaborative international clinical trials testing full dose anticoagulation with heparin (a blood thinner) in both moderately ill and critically ill patients has found the treatment improves ...
LANSING, Mich., Aug. 19 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new ...
Many patients requiring pacemaker or implantable cardioverter–defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging ...
Heparin, the common anticoagulant medication, inhibits the SARS-Cov2 virus spike protein, by reducing the virus' ability to attach to human cells and infect them, said an international team of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results